Glioblastoma (Brain Cancer) Fund

The University of Liverpool’s Glioblastoma (Brain Cancer) Fund is supporting ground-breaking research into immunotherapy, a promising new treatment for glioblastoma.

Glioblastoma is the most common type of primary brain cancer. Despite intensive treatment with surgery, radiotherapy and chemotherapy, people with glioblastoma on average lose 20 years of life – the highest average years of life lost compared to other cancers.

Immunotherapy is a new type of treatment that is revolutionising oncology by manipulating the body’s own immune system into fighting cancer. Researchers at the University of Liverpool, working with The Walton Centre NHS Foundation Trust, are studying the immune system response in long-term survivors and comparing the results with those patients who do not respond to treatment.

Our donor community has been pivotal in supporting this innovative research. Including funding the Kevin O’Riordan Brain Tumour PhD Fellowship position to enable Dr Michael Cearns to lead the project alongside neurosurgeons Professor Michael Jenkinson and Dr Rasheed Zakaria, and world leading expert in immuno-oncology Professor Christian Ottensmeier. 

Thank you to everyone who has supported the campaign so far.